About
Technology
Issues
FAQ
Links
Official Page
Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.